QDEL Kronos AI forecast
A 30-trading-day price forecast for QuidelOrtho Corporation (QDEL) from Kronos AI, an open-source foundation model trained on candlestick charts.
Kronos AI's median forecast puts QuidelOrtho Corporation at $15.38 on 2026-12-08, +13.2% from the last close of $13.59 on 2026-10-27. Eight out of ten sampled paths end between $10.93 and $16.02, and 6 of the 8 paths finish above today's price.
Forecast path
median, with the 10–90% band of the sampled pathsOpen the interactive forecast → Full analysis of QDEL
The forecast, week by week
| Date | Median | Low (10%) | High (90%) |
|---|---|---|---|
| 2026-11-03 | $14.17 | $13.67 | $14.76 |
| 2026-11-10 | $14.79 | $13.92 | $15.96 |
| 2026-11-17 | $15.37 | $13.28 | $16.99 |
| 2026-11-24 | $15.39 | $11.34 | $17.54 |
| 2026-12-01 | $14.31 | $10.35 | $16.31 |
| 2026-12-08 | $15.38 | $10.93 | $16.02 |
What is Kronos AI?
Kronos is an open-source foundation model for financial candlesticks, pre-trained on K-line data from more than 45 exchanges. Gnzub runs it on each stock's last 120 daily bars and samples several possible futures, so the forecast is a range of outcomes rather than one confident line. It is a statistical model, not an analyst: it reads price patterns only and knows nothing about news, earnings or the business.
Questions
- What is the Kronos AI forecast for QDEL?
- Kronos AI's median forecast for QDEL is $15.38 in 30 trading days, +13.2% from the last close, with a 10–90% range of $10.93 to $16.02.
- Is the QDEL Kronos forecast a buy or sell signal?
- No. It is the output of a statistical model that reads price history only. It is not investment advice, and the range shows how uncertain the model is.
- How often is the forecast updated?
- The forecasts are regenerated regularly; this one starts from the close of 2026-10-27.
Kronos forecasts for similar companies
- IDXX — IDEXX Laboratories Inc.
- LNTH — Lantheus Holdings Inc.
- ORKA — Oruka Therapeutics Inc.
- NEOG — Neogen Corporation
- CLDX — Celldex Therapeutics Inc.
- NTLA — Intellia Therapeutics Inc.